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Abstract
One third of acute myeloid leukemias (AMLs) are characterized
by the aberrant cytoplasmic localization of nucleophosmin
(NPM) due to mutations within its putative nucleolar locali-
zation signal. NPM mutations are mutually exclusive with
major AML-associated chromosome rearrangements and are
frequently associated with a normal karyotype, suggesting that
they are critical during leukemogenesis. The underlying
molecular mechanisms are, however, unknown. NPM is a
nucleocytoplasmic shuttling protein that has been implicated
in several cellular processes, including ribosome biogenesis,
centrosome duplication, cell cycle progression, and stress
response. It has been recently shown that NPM is required
for the stabilization and proper nucleolar localization of
the tumor suppressor p19Arf. We report here that the AML-
associated NPM mutant localizes mainly in the cytoplasm due
to an alteration of its nucleus-cytoplasmic shuttling equilibri-
um, forms a direct complex with p19Arf, but is unable to protect
it from degradation. Consequently, cells or leukemic blasts
expressing the NPM mutant have low levels of cytoplasmic Arf.
Furthermore, we show that expression of the NPM mutant
reduces the ability of Arf to initiate a p53 response and to
induce cell cycle arrest. Inactivation of p19Arf, a key regulator of
the p53-dependent cellular response to oncogene expression,
might therefore contribute to leukemogenesis in AMLs with
mutated NPM. (Cancer Res 2006; 66(6): 3044-50)
Introduction
The gene encoding for nucleophosmin (NPM ; also known as B23,
NO38, or numatrin) is involved in several tumor-associated
chromosome translocations, which result in the formation of
fusion proteins retaining the NH2 terminus of NPM [NPM-ALK (1),
NPM-RAR (2), and NPM-MLF1 (3)]. It is generally thought that the
NPM component does not contribute biological signaling to the
transforming potential of these fusion proteins but instead
provides a dimerization interface for the oligomerization and the
oncogenic conversion of the various NPM partners (ALK, RAR,
and MLF1; ref. 4). More recently, mutations of NPM have been
described in about 35% of acute myeloid leukemias (AMLs; ref. 5).
NPM mutations are usually associated with a normal karyotype
(85%) and are mutually exclusive with the other AML-associated
major genetic abnormalities, suggesting that they represent an
initiating event in myeloid leukemogenesis, and that alterations of
NPM might contribute directly to the transformation process. The
underlying mechanism(s) remain, however, unknown.
NPM is an abundant and ubiquitously expressed nucleolar
phosphoprotein, which functions as a molecular chaperone (6)
and shuttles between nucleus and cytoplasm (7). It regulates cell
proliferation (8, 9), although its specific effect remains controversial,
and stimulates cell survival after DNA damage (10, 11). NPM
physically interacts with many cellular proteins, including the tumor
suppressors p53 (8) and Arf (ref. 12; p19Arf in mouse and p14ARF in
human). We (13) and others (14) have recently shown that the
nucleolar Arf protein is delocalized and markedly unstable in the
absence of NPM expression, thus suggesting that one physiologic
function of NPM is to ensure the proper localization of Arf and to
protect it from degradation. We report here our investigations aimed
at defining whether the leukemia-associated mutant of NPM
(NPMmut) alters localization and/or stability of Arf.
Materials and Methods
Cell culture, transfection, and infection. Mouse embryo fibroblasts
(MEF), Phoenix, and NIH cells were cultured at 37jC and 5% CO2 in DMEM
supplemented with 10% fetal bovine serum. Transient transfections were
done using the standard calcium phosphate precipitate method for Phoenix,
FuGENE 6 (Roche, Indianapolis, IN) for MEFs and LipofectAMINE
(Invitrogen, Carlsbad, CA) for NIH-3T3 cells. For infection experiments, we
used a Pinco-based vector expressing green fluorescent protein (GFP; control
vector), GFP-NPM1, or GFP-mutant NPM fusion proteins. Empty or
recombinant retroviral vectors were transfected into Phoenix packaging cell
lines, and after 48 hours, the supernatants were used to infect target cells.
Lineage minus (lin) hematopoietic cells were purified from the bone
marrow of 8- to 12-week strain 129SvEv mice by depletion of cells expressing
myeloid, erythroid, and lymphoid differentiation markers, using a StemSep
Murine Progenitor Enrichment kit (Stem Cell Technologies, Vancouver,
British Columbia, Canada). Lin cells were grown for 2 to 3 days in RPMI
containing interleukin-3 (20 ng/mL), interleukin-6 (20 ng/mL), and stem cell
factor (100 ng/mL). The cells were then plated onto retronectin-coated
(Takara-Shuzo, Shiga, Japan), non–tissue culture–treated plates and exposed
to the supernatant of packaging, ecotropic Phoenix cells transiently
transfected with the indicated retroviral vectors (Pinco or Pinco-NPMmut).
Infected, GFP-positive cells were sorted using a Becton Dickinson (Franklin
Lakes, NJ) FACS Vantage instrument. Cytospinswere done of the infected lin
cells immediately after sorting. The cells were fixed with PBS containing 4%
paraformaldehyde and stained for immunofluorescence analysis.
Plasmids. We amplified the mutated form of NPM (NPMmut) directly
from the mRNA of one patient using the following primers: forward, 5V-
GGTTGTTCTCTGGAGCAGCGTTCT; reverse, 5V-ACTGCCAGATAT-
CAACTGTTACAG. The amplified product was cloned into pCR2.1TOPO
(Invitrogen) and then subcloned into the Pinco retroviral vector or
reamplified using two primers containing a BamHI site at the 5V-term
( forward, 5V-ATGCGGATCCCCGATGGAAGATTCGATGGAC) and a XbaI
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site at the 3V-term (reverse, 5V-ATGCTCTAGAGTTTAACTATTTTCTTAAA-
GAGAC) and cloned, in frame, with the HA-flag of the pBabe-flag-HA
retroviral or pCDNA3 (Invitrogen) vectors, or with the GFP tag of the
pEGFP vector (Clontech, Mountain View, CA). NPM1 has been amplified
with the following primers: forward, 5V-ATGCGGATCCCCGATGGAAGA-
TTCGATGGAC; reverse, 5V-ATGCGGATCCATTTTCTTAAAGAGACTT-
CCTCCA, and then cloned in frame with GFP in pEGFP (Clontech) and
flag in pCDNA-flag (Invitrogen). NPM2 was amplified with the following
primers: forward, 5V-ATGCAGATCTCCGATGGAAGATTCGATGGAC;
reverse, 5V-ATGCAGATCTGACTGTTCAATGCGCTTTTTCTAT and then
cloned in frame with GFP in pEGFP (Clontech) and flag in pCDNA-flag
(Invitrogen).
Human biopsy staining. Bonemarrow biopsieswere fixed and decalcified
in Mielodec (Bio-Optica, Milan, Italy). Three- to 5-Am-thick tissue sections
were pretreated with an antigen retrieval solution [0.01 mol/L EDTA buffer
(pH 8)] at 99jC for 30 minutes and were then probed with the anti-NPMa
monoclonal antibody and with the anti-p14ARF (C-18, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) goat polyclonal antibody, at aworking dilution of 1:20 and
1:400, respectively. The reaction was developed using the detection kits LSAB
AP for NPM and LSAB horseradish peroxidase for p14 (DakoCytomation,
Glostrup, Denmark), according to the manufacturer’s instructions.
Immunoblotting and immunoprecipitation. Western blot and
immunoprecipitation experiments were done as described (8). The
following primary antibodies were used: polyclonal anti-p19Arf (1:1,000;
Abcam, Cambridge, MA), monoclonal anti-NPM (NPMa, that recognizes
NPM1, NPM2, and NPMmut; ref. 15), monoclonal anti-flag (1:1,000; Sigma,
St. Louis, MO), polyclonal anti-NPM (B19; ref. 8), anti-p21 (F5; Santa Cruz
Biotechnology), or anti-p53 (a gift from Dr. K. Helin, Biotech Research and
Innovation Center, Copenhagen, Denmark).
Immunofluorescence. Immunofluorescence analysis was done as
previously described (8). The antibodies used were polyclonal anti-p19Arf
(1:200; Abcam) and monoclonal anti-NPM [cytoplasmic NPM (NPMc),
specific for NPM1, and NPMa].
Bromodeoxyuridine staining. NIH MT-Arf cells were infected with
control retroviruses or retroviruses expressing NPMmut or NPM1. Cells
were then seeded on coverslips and treated for 24 hours with (or without)
zinc (Zn), to induce Arf protein expression. After treatment, 33 Amol/L
bromodeoxyuridine (BrdUrd) was added to the medium for 15 minutes, and
cells were fixed with 4% paraformaldehyde and analyzed by immunofluo-
rescence using an anti-BrdUrd antibody.
Results
Expression of NPM1, NPM2, and NPMmut. Approximately one
third of AMLs are characterized by the aberrant cytoplasmic
localization of NPM due to mutations in the most 3Vof its coding
exons (5). Althoughmolecularly heterogeneous, all mutations lead to
a frameshift in the region encoding for the COOH terminus of the
NPM protein. We cloned a full-length mutant NPM cDNA from the
leukemic blasts of one AML patient carrying cytoplasmic NPM (data
not shown) and a duplication of the TCTG tetranucleotide at
positions 956 to 959 of the NPM nucleotide sequence (Fig. 1A). This
insertion, which is representative of the most frequent type of NPM
Figure 1. Expression of NPM1, NPM2,
and NPMmut. A, DNA and protein sequence
of WT and NPMmut. Tetranucleotide
insertion and the novel mutant amino
acid residues (red). Stop codons (*). B,
schematic representation of NPM isoforms
and mutant. NoLS, nucleolar localization
signal; HoD, homodimerization domain.
Right, amino acid positions (aa) of
relevant protein regions. C, MEFs from
NPM-deficient mice (p53/NPM/: dKO;
see text) were transfected with flag-NPM1,
flag-NPM2, and HA-flag-NPMmut; lysed;
and analyzed by Western blotting using
antibodies against flag or NPM, as indicated.
Control, lysates from p53/ fibroblasts.
The faster migrating anti-NPM polypetide
seen in the NPM1, NPM2, and NPMmut
lanes might represent an NH2-terminal
degradation product, which is not recognized
by the anti-Flag antibody. D, p53/
MEFs were transfected with GFP-NPM1,
GFP-NPM2, GFP-NPMmut, or infected
with untagged NPMmut (pinco vector).
Infected cells expressed the GFP
[green fluorescence merged with
4V,6-diamidino-2-phenylindole (dapi )]
as marker, and the NPMmut protein,
as revealed by using the NPMa antibody
(red fluorescence).
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mutations found in AMLs (5), causes a frameshift that substitutes
the last seven amino acids (WQWRKSL) of the NPM protein with
11 novel residues (CLAVEEVSLRK; Fig. 1A-B). The NPMmut cDNA
was then tagged with hemagglutinin (HA), HA/flag, or GFP and
cloned within different mammalian expression vectors (the Pinco
retrovirus or cytomegalovirus promoter-based plasmids). As con-
trols, we used cDNAs representative of the two alternative
transcripts of the NPM locus, which encode proteins differing at
their extreme COOH terminus (NPM1 or NPM2; Fig. 1B ; ref. 16).
Expression of tagged NPM1, NPM2, and NPMmut cDNAs in NPM
knockout MEFs yielded polypeptides of the expected size, which
were specifically recognized by anti-NPM or anti-tag antibodies (see
Fig. 1C for representative results). GFP-tagged constructs were then
transfected into MEFs and analyzed by direct epifluorescence. GFP-
NPM1 showed a nucleolar localization pattern, GFP-NPM2 localized
to both nucleoplasm and nucleoli, whereas the GFP-NPMmut was
detected in the nucleoli, nucleoplasm, and cytosol (Fig. 1D). This
localization pattern of the NPMmut protein was not influenced by
fusion of NPMmut with GFP, because it was also seen with nontagged
(Fig. 1D) andHA/flag– (data not shown)NPMmut. The same intracellular
localization pattern was observed upon retrovirus-mediated expres-
sion of untagged NPMmut into haematopoietic precursor cells (data
not shown). It seems, therefore, that as reported (5), the NPMmut has
the aberrant property of localizing within the cytoplasm.
NPM mutant induces delocalization and destabilization of
Arf protein.NPM is required for the proper nucleolar localization of
Arf as well as for its stability (13, 14). We thus investigated the effects
of NPMmut expression on Arf localization and stability. Expression
of the NPMmut but not NPM1 or NPM2 in MEFs provoked
delocalization of p19Arf to the cytoplasm (Fig. 2A, left) in virtually
all the transfected cells (Fig. 2A, right). This effect was evident
also upon retrovirus-mediated expression of untagged NPMmut into
hematopoietic precursor cells (Fig. 2B). Finally, immunohistochem-
ical analysis of bone marrow biopsies from AML patients carrying
mutations and cytoplasmic delocalization of NPM revealed the
presence of weak anti-p14ARF cytoplasmic staining in three of three
positive cases (Fig. 2C), suggesting that cytoplasmatic delocalization
of p14ARF is a characteristic of AMLs with NPM mutations.
The overall anti-Arf staining intensity seemed lower in MEFs
expressing the NPMmut (Fig. 2A) or in leukemia blasts from AML
patients carrying mutations of NPM (Fig. 2C). To investigate
whether Arf protein levels are decreased following NPMmut
expression, NPMmut and NPM1 were cotransfected with p19arf
into p19Arf/ MEFs (together with a h-galactosidase expressing
vector to normalize transfection efficiency) and their expression
levels analyzed by Western blotting. Consistently, lower levels of Arf
were found in cells cotransfected with the NPMmut (Fig. 3A, left)
but not with wild-type (WT) NPM1 (Fig. 3A, middle). Similar results
were obtained using one clone of NIH 3T3 carrying a conditional
(Zn inducible) p19Arf allele (MT-Arf ref. 17). Indeed, levels of Zn-
induced p19Arf expression (and of the p53 target p21 gene) were
lower in MT-Arf cells expressing GFP-NPMmut (Fig. 3A, right).
To preliminary investigate the mechanisms underlying the effects
of NPMmut on levels of p19Arf expression, we investigated the
effects of NPMmut on p19Arf protein stability. MT-Arf cells were first
infected with a control retrovirus or with a retrovirus expressing
NPMmut and then treated with Zn for 24 hours, to induce Arf
expression. At the end of the Zn treatment, cells were treated with
cycloheximide, to block de novo protein synthesis, and p19Arf levels
analyzed by Western blotting at different time points (tubulin was
used to normalize for protein levels, due to its relatively high
stability; ref. 13). As shown in Fig. 3B , levels of p19Arf remained
constant up to 8 hours after cycloheximide treatment in the
control cells, whereas at the same time point they were significantly
reduced in the presence of GFP-NPMmut expression, thus suggest-
ing that NPMmut induces a reduction of the half-life of p19Arf.
Figure 2. NPMmut delocalizes p19Arf.
A, left, immunofluorescence analysis of
p53/ MEFs transfected with expression
vectors for GFP-NPM1, GFP-NPM2, and
GFP-NPMmut, as indicated. Cells were
stained with an antibody anti-p19Arf (red).
Right, percentage of cells showing
cytoplasmic p19arf staining in cultures of
p53/ MEFs transfected with expression
vectors for GFP-NPM1, GFP-NPM2, and
GFP-NPMmut, as indicated. Columns,
results of three independent transfections.
Approximately 200 cells were counted for
each sample. B, lin hematopoietic mouse
cells were infected with the control Pinco
retrovirus or with a Pinco retrovirus
expressing NPMmut, as indicated,
FACS-sorted, and stained with an anti-p19Arf
antibody. C, left, immunohistochemical
analysis of NPM and p14Arf localization done
on human bone marrow biopsies from two
AML patients, one carrying mutated and
NPMc, the other carrying WT and nucleolar
NPM (NPMn ). Right, percentage of cells
showing cytoplasmic (white column) or
nuclear (black column) anti-p14 staining
by immunohistochemical analysis in AML
samples. Columns, average of three different
patients for each category (NPMc and
NPMn). Two hundred cells have been
counted for each sample.
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Expression of p19Arf induces cell cycle arrest of MT-Arf
fibroblasts (17). Therefore, to investigate the biological effects of
NPMmut on p19Arf activity, we evaluated, by the BrdUrd
incorporation test, the number of cycling cells after Zn treatment
in MT-Arf cells infected with the control retrovirus, or with
retroviruses expressing GFP-NPMmut or GFP-NPM1. As shown in
Fig. 3C , expression of the NPMmut reduced significantly (P = 0.003)
the ability of p19Arf to block S-phase entry, whereas the WT NPM1
protein did not show any effect. The effects of GFP-NPM1 or GFP-
NPMmut on the levels of p19Arf and p53 expression in this
experiment are shown in Fig. 3B . Taken together, these data suggest
that expression of NPMmut causes delocalization and destabiliza-
tion of Arf, thus antagonizing its ability to induce cell cycle arrest.
NPMmut forms a complex with p19Arf. NPM forms, in vivo and
in vitro , homo-oligomeric complexes containing five or six
molecules (18). Because the NPMmut retains the homodimeriza-
tion domain of NPM (Fig. 1B), we investigated whether the effect
of NPMmut on Arf was due to its interaction with endogenous
NPM. To this end, we first evaluated the effect of NPMmut on the
localization of endogenous NPM [using a monoclonal antibody
(NPMc) directed against the portion of NPM that is lost in the
NPMmut; see Materials and Methods]. Surprisingly, in cells
expressing NPMmut, endogenous NPM localizes predominantly in
the nucleolus and is only marginally delocalized in the cytoplasm
(Fig. 4A, b). Because Arf is instead predominantly cytoplasmic in
the same cells (Fig. 4A, e), NPMmut might delocalize Arf through
a direct interaction. Therefore, we investigated the effects on Arf
protein localization upon expression of the NPMmut (and NPM1 or
NPM2, as controls) in MEFs derived from NPM null mice. To
this end, we used cells derived from double NPM/p53/ mice
(dKO). In fact, we have shown that lack of NPM leads to
accumulation of DNA damage and p53-dependent apoptosis, thus
preventing the possibility of culturing NPM/ cells, whereas the
transfer of the NPM/ mutation into a p53/ background (dKO)
allows propagation of NPM-deficient cells in vitro (13). As expected,
exogenously expressed GFP-NPM1 or GFP-NPM2 localized in the
nucleolus or in the nucleoplasm, respectively (Fig. 4A, l and o).
Strikingly, instead, the NPMmut was exclusively cytoplasmic in the
dKO cells (Fig. 4A, g ) and caused the cytoplasmic delocalization of
Arf (Fig. 4A, h), suggesting that the NPMmut interacts directly with
Arf. This was then confirmed by coimmunoprecipitation experi-
ments showing that NPMmut, NPM1, or NPM2 all form stable
complexes with Arf in the dKO cells (Fig. 4B). Moreover, the
restoration of NPM1 (Fig. 4A, m) or NPM2 (Fig. 4A, p) expression in
Figure 3. Decreased stability and reduced biological activity of cytoplasmic p19Arf. A, left and middle, Western blotting analysis of p19Arf and NPM expression in
NIH3T3 cells cotransfected with p19Arf and a control vector (Arf) or p19Arf and flag-tagged NPMmut (left ) or flag-tagged NPM1 (middle ). Transfection efficiency was
evaluated and normalized using a cotransfected h-galactosidase expressing plasmid. Representative of three that gave comparable results. Right, Western blotting
analysis of p19Arf, NPM, p21, and vinculin expression in MT-Arf cells infected with a control retrovirus (NPMmut: ) or with a retovirus expressing GFP-NPMmut
(NPMmut: +) and treated (Zn: +) or not (Zn: ) for 24 hours with 80 Amol/L ZnSO4. B, Western blotting analysis of p19Arf and tubulin expression in Mt-Arf cells infected
with the control retrovirus or with a retrovirus expressing NPMmut, as indicated. Cells were for treated 24 hours with 80 Amol/L ZnS04, and then with 100 Amol/L
cyclohexamide (CHX ). Cells were harvested at the indicated time points, lysed, and analyzed by Western blotting, as indicated. C, left, evaluation of BrdUrdpositive
cells in MT-Arf cells infected with a control retrovirus (Ctrl. ), with retoviruses expressing GFP-NPMmut (NPMmut) or GFP-NPM1 (NPM1), and treated (Zn: +)
or not (Zn: ) for 24 hours with 80 Amol/L ZnSO4. The percentage of BrdUrd positive cells in the ZnSO4-treated samples has been normalized with that of the
corresponding untreated cells (considered as 100%). *, P = 0.0031, statistical significance of the difference in BrdUrd-positive cells in the control and NPMmut cells after
Zn induction. The experiment has been done twice, each time in triplicate; f200 cells have been counted for each sample. Right, the same cell samples as described
in the left panel have been analyzed by Western blotting for the indicated proteins.
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NPM-deficient cells caused a marked increase in the levels of
nucleolar or nucleoplasmic Arf, respectively, whereas NPMmut had
no effects on p19Arf protein levels (Fig. 4A, h). Taken together, these
findings indicate that the effects of the NPMmut on Arf localization
is not exerted through its interaction with endogenous NPM and
support a model, whereby NPMmut competes with WT NPM for
Arf binding and targets Arf to the cytoplasm, where it becomes
more susceptible to degradation.
Altered nuclear-cytoplasmic shuttling of NPM. In the
absence of endogenous NPM (dKO cells), the NPMmut localized
exclusively in the cytoplasm, without any accumulation in the
nucleoli or in the nucleoplasm (Fig. 5A). The lack of nucleolar
staining of the NPMmut was expected, because the region of
NPM1 responsible for its nucleolar localization is partially lost in
the NPMmut (Fig. 1B). Consistently, NPM2, which lacks this same
region, is also nuclear diffuse in dKO cells (Fig. 5A). However,
the inability of NPMmut to enter the nucleus is surprising,
because it retains the two NPM nuclear localization signals
(Fig. 1B). NPM is a protein that continuously shuttles between
nucleus and cytoplasm, and that, at the steady state, is
predominantly localized in the nucleus. Therefore, we investigated
whether NPMmut retains the ability of WT NPM to shuttle
between nucleus and cytoplasm. Controls and dKO cells were
transfected with GFP-NPMmut and then treated with leptomycin,
a drug that inhibits nuclear export (19). Strikingly, treatment
with leptomycin leads to a massive accumulation of the NPMmut
in the nucleus, both in the presence and in the absence of
endogenous NPM (Fig. 5B). Likewise, cytoplasmic Arf was entirely
relocalized in the nucleus (Fig. 5C). These findings show that
NPMmut is still able to shuttle between nucleus and cytoplasm,
and that the leukemia-associated mutation imposes a predomi-
nant cytoplasmic localization at the steady state. Because
NPMmut forms a stable complex with Arf, it is then expected
that also Arf becomes cytoplasmic in cells expressing NPMmut
(as shown in Fig. 5C).
Discussion
Arf is a potent tumor suppressor that protects cells from
oncogenic conversion, through either p53-dependent and p53-
independent pathways (20). Biologically, activation of Arf induces
cell cycle arrest or apoptosis, two cellular responses that depend
on intact p53 and require inactivation of the Mdm2 oncogene,
a critical factor in the termination of the p53 response. Although the
underlying mechanisms are not yet fully elucidated, they involve
binding of Arf to Mdm2 in the nucleus, thus allowing dissociation
of the p53/mdm2 complex and stabilization of p53 (21).
It has been hypothesized that disruption of the ARF/Mdm2/
p53 pathway is a critical step during transformation. Indeed,
genetic alterations leading to inactivation of p53 or Arf, or to
increased expression of Mdm2, are found in most human tumors
(22). A notable exception is represented by hematopoietic
tumors,5 including AMLs carrying mutations of NPM (23), where
Figure 4. Mutant NPM forms a
stable complex with p19Arf protein.
A, immunofluorescence analysis of
endogenous NPM (b) and p19Arf (e )
localization in p53/ MEFs transfected
with GFP-NPMmut (a and d ).
Immunofluorescence analysis of p19Arf
(h, m , and p ) in dKO MEFs transfected with
GFP-NPMmut (g), GFP-NPM1 (l ), and
GFP-NPM2 (o ), as indicated. B, dKO
MEFs were transfected with the indicated
expression vectors (flag-tagged NPM1 and
NPM2; HA/flag-tagged NPMmut) and total
lysates were immunoprecipitated with
anti-flag antibodies. Total lysates (input )
and the various immunoprecipitates were
then resolved by SDS-PAGE and blotted
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genetic alterations of members of the ARF/Mdm2/p53 pathway
are relatively rare. In these tumors, however, other genetic
alterations might be selected, which lead to the functional
inactivation of the ARF/Mdm2/p53 pathway. For example, the
leukemia-associated bcr-abl or PML-RAR oncogenes have been
shown to activate pathways leading to functional inactivation
of p53 (24, 25). We reported here that the ability of Arf to
stabilize p53 is diminished when Arf is expressed in the presence
of the mutated form of NPM, and that under these circum-
stances, the resulting levels of the p53 target gene p21 are
reduced, as well as the ability of p19Arf to induce cell cycle arrest.
These findings show that cytoplasmic NPM interferes with the
biological activity of p19Arf, thus suggesting that one possible
mechanism through, which mutated NPM contributes to leukemo-
genesis in AMLs is by antagonizing the tumor suppressor function
of p19Arf.
We showed that mutated NPM exerts two distinct effects on
p19Arf: cytoplasmic delocalization and decreased protein stability,
both of which might well affect the function of p19Arf. The AML-
associated mutations of NPM create a de novo nuclear export
signal at its NH2 terminus, which leads to increased Crm1-
dependent export of the altered protein to the cytoplasm (26).
The NPM mutation, however, does not affect the ability of NPM to
form a complex with p19Arf in vivo , as shown by the fact that
the mutated NPM forms a complex with p19Arf in cells lacking
expression of WT NPM. Therefore, it seems that the mutated
NPM sequesters p19Arf in the cytoplasm by competing with the
WT protein, which remains instead mainly localized in the
Figure 5. NPMmut shows altered
nucleus-cytoplasmic shuttling properties.
A, fluorescence analysis of dKO cells
transfected with GFP-NPMmut (a),
GFP-NPM1 (e ), and GFP-NPM2 (g),
or infected with untagged NPMmut
(pinco vector; c ). The infected cells
expressed GFP [green staining merged
with 4V,6-diamidino-2-phenylindole (dapi )]
as marker and the NPMmut protein
(as revealed by staining with the
NPMa antibody; red staining). B,
immunofluorescence analysis of p53/
and dKO MEFs transfected with
GFP-NPMmut treated or not with
leptomycin for 8 hours, as indicated.
C, immunofluorescence analysis of p53/
cells transfected with GFP-NPMmut, treated
or not for 8 hours with leptomycin and
stained with an anti-p19Arf specific
antibody (red ), as indicated.
Mutated NPM Delocalizes Arf
www.aacrjournals.org 3049 Cancer Res 2006; 66: (6). March 15, 2006
nucleus. Because p19Arf prevents Mdm2-mediated ubiquitination
(and degradation) of p53 by interacting with Mdm2 in the
nucleus (27), it is expected that the delocalization of p19Arf to the
cytoplasm by mutated NPM antagonizes Arf-mediated activation
of p53.
We have recently shown that the half-life of p19Arf is markedly
reduced in cells deficient for NPM expression, suggesting that NPM
contributes to the stabilization of p19Arf (13). Because NPM
possesses chaperone-like activities and forms high-stoichiometry
complexes with p19Arf (28), it is possible that NPM functions as a
chaperone for p19Arf, allowing its correct folding and/or protecting
it from degradation. This function of NPM, however, is lost in the
mutant NPM, despite its ability to form a stable complex with
p19Arf. Treatment of cells expressing mutant NPM with leptomycin
induces the nuclear relocalization of both NPMmut and p19Arf,
and, notably, increases the levels of p19Arf,6 thus suggesting that the
degradation of p19Arf in the presence of the mutated NPM is due to
its cytoplasmic localization. Although further studies are required
to elucidate the molecular mechanisms involved in the degradation
of p19Arf in AMLs carrying mutated NPM, they might provide novel
targets for the reactivation of the p19Arf/p53 pathway in AMLs with
mutated NPM.
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